3.0.0 2495 2023-01-01T23:42:39Z 2023-01-01T23:42:39Z Senate S 2021-07-28 117 ssfi00 Finance Committee Senate Standing Referred to 2021-07-28T17:20:16Z Protecting our Pharmaceutical Supply Chain from China Act of 2022 117 7121 HR 2022-03-28 Referred to the Subcommittee on Health. Related bill CRS ABC Safe Drug Act 117 3401 S 2021-12-15 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Related bill CRS 2021-07-28 ssfi00 Finance Committee Senate Read twice and referred to the Committee on Finance. IntroReferral 2021-07-28 Introduced in Senate IntroReferral 10000 9 Library of Congress C001095 Sen. Cotton, Tom [R-AR] Tom Cotton R AR N B001243 Sen. Blackburn, Marsha [R-TN] Marsha Blackburn R TN 2021-07-28 True C001098 Sen. Cruz, Ted [R-TX] Ted Cruz R TX 2021-07-28 True S001217 Sen. Scott, Rick [R-FL] Rick Scott R FL 2021-07-28 True B001310 Sen. Braun, Mike [R-IN] Mike Braun R IN 2021-07-28 True Health Asia Business expenses China Drug safety, medical device, and laboratory regulation Government information and archives Health care costs and insurance Health programs administration and funding Health technology, devices, supplies Income tax deductions Manufacturing Military medicine Military procurement, research, weapons development Prescription drugs Public contracts and procurement Trade restrictions Veterans' medical care Health 00 2021-07-28 Introduced in Senate 2022-07-25T18:33:53Z Protecting our Pharmaceutical Supply Chain from China Act of 2021

This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing ingredients manufactured in China, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.

The Food and Drug Administration shall maintain (1) a list of foreign-sourced drugs and active ingredients that are critical for consumer health and safety, and (2) another list identifying such drugs that are produced exclusively in China or use ingredients produced in China.

The bill phases in a restriction on federal health care programs purchasing drugs with active ingredients manufactured in China. By January 1, 2024, such programs may not purchase a drug with any active ingredients from China. The Department of Health and Human Services may issue a waiver for an agency or program that is unable to meet this requirement, but no waiver may apply to drugs purchased in or after 2026.

Each drug must have labeling listing the country of origin of each active ingredient, and a drug without this labeling shall be deemed misbranded.

The bill allows 100% tax expensing for qualified pharmaceutical and medical device manufacturing property placed in service between 2020 and 2026.

]]> Protecting our Pharmaceutical Supply Chain from China Act of 2021 Official Title as Introduced A bill to require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of drugs manufactured in the People's Republic of China, and for other purposes. Introduced in Senate IS Display Title Protecting our Pharmaceutical Supply Chain from China Act of 2021 Short Title(s) as Introduced Protecting our Pharmaceutical Supply Chain from China Act of 2021 Introduced in Senate IS Introduced in Senate 2021-07-28T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-117s2495is/xml/BILLS-117s2495is.xml 2021-07-28 Read twice and referred to the Committee on Finance. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.